Qiucheng Li,Yau-Tuen Chan,Junyu Wu et al.
Qiucheng Li et al.
Deciphering the mechanistic links between aging and cancer remains a central challenge in biomedical research. This review begins by presenting recent epidemiological data on cancer incidence across age groups, underscoring the complex and ...
Tumor-draining lymph nodes shape the tumor microenvironment through enrichment of tumor-reactive effector-exhausted CD8+ T cells [0.03%]
肿瘤引流淋巴结通过富含肿瘤反应性效应耗竭的CD8+t细胞来塑造肿瘤微环境
Deyang Kong,Lin Feng,Yu Sun et al.
Deyang Kong et al.
Tumor-draining lymph nodes are central to anti-tumor immunity and influence the response to immunotherapy. Colorectal cancers with microsatellite instability and microsatellite stability differ substantially in tumor biology, prognosis and ...
Oladapo F Fagbohun
Oladapo F Fagbohun
Targeting endoplasmic reticulum export disrupts metabolic resilience in multiple myeloma [0.03%]
靶向内质网转运可破坏多发性骨髓瘤的代谢适应力
Utku Horzum,Herbert Oberacher,Margot Haun et al.
Utku Horzum et al.
Multiple myeloma (MM) is characterized by the production and secretion of large quantities of immunoglobulins, making this malignancy highly dependent on mechanisms that maintain cellular proteostasis. While significant clinical progress ha...
Protein lactylation in health and diseases: molecular mechanisms, biological significance, and clinical implications [0.03%]
蛋白质乳酰化在健康与疾病中的作用：分子机制、生物意义及临床意义
Yue Yang,Ying He,Ziyi Zhang et al.
Yue Yang et al.
Protein lysine lactylation (Kla) is a newly identified post-translational modification (PTM), in which lactyl groups are transferred to specific lysine residues in proteins. As a crucial intermediary between cellular metabolism and epigenet...
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial [0.03%]
奥雷布替尼与化疗免疫疗法在初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中的疗效比较：一项随机III期临床试验
Fei Li,Keshu Zhou,Wei Xu et al.
Fei Li et al.
Orelabrutinib is a potent, irreversible, and highly-selective BTK inhibitor that has been approved for the treatment of relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). This randomized, phase 3 study (...
Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial [0.03%]
替雷利珠单抗（PD-1抗体）联合化疗新辅助治疗晚期卵巢上皮癌的Ⅱ期NAIVE研究
Zhigang Zhang,Jing Fei,Sangting Lao et al.
Zhigang Zhang et al.
The clinical efficacy and immune modulation of neoadjuvant immunochemotherapy for epithelial ovarian cancer (EOC) remain uncertain. To clarify these effects, the NAIVE trial (NCT04815408), a prospective phase II study, evaluated the efficac...
Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent [0.03%]
一种可通过血脑屏障的非处方药物化学遗传学抑制方法
Steven O Devenish,Sahil D Patel,Laura V Ussingkær et al.
Steven O Devenish et al.
Chemogenetics allows the controllable manipulation of brain circuits upon delivery of a selective activating ligand, and has been invaluable in dissecting brain circuits underlying many behaviours. The Gαi/o-coupled designer muscarinic rec...
Osimertinib-induced cardiotoxicity is driven by HDAC-dependent epigenetic repression and rescued by vorinostat [0.03%]
柳氮替尼诱导的心脏毒性由组蛋白脱乙酰酶依赖的表观遗传抑制驱动，并可通过伏立诺他逆转
Angelica Toro Cora,Arvind Singh Bhati,Allen Sam Titus et al.
Angelica Toro Cora et al.
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), has improved outcomes in non-small cell lung cancer (NSCLC) patients harboring the T790M mutation; however, emerging clinical evidence indicates a risk of cardiotoxicity....
Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection [0.03%]
部分下调血小板糖蛋白VI的低亲和力抗体可提供持续且安全的抗血栓保护作用
Stefano Navarro,Sarah Beck,Sabrina I Bonfiglio et al.
Stefano Navarro et al.
Glycoprotein (GP) VI is a platelet-specific activating receptor for collagen and fibrin(ogen), and a promising target for antithrombotic therapy. Inhibitory Fab fragments against GPVI provide robust protection in mouse models of arterial th...